top of page


Pfizer and Blackstone agree up to $1.5 billion in development funding for monthly GLP-1 obesity candidate berobenatide
Pfizer and Blackstone Life Sciences have agreed a development co-funding arrangement of up to $1.5 billion for investigational once-monthly GLP-1 therapy berobenatide, sharing clinical development risk while Pfizer retains control of the programme.

nuaxia
4 days ago2 min read


FDA approves Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer
The FDA has approved Pfizer's Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer, expanding the combination into an earlier treatment setting.

nuaxia
Oct 272 min read


Pfizer signs Enodia Therapeutics research and licensing agreement worth more than $500 million for Sec61 protein degradation
Pfizer has entered a research and licensing collaboration with Enodia Therapeutics worth potentially more than $500 million to develop small-molecule therapies targeting protein synthesis through Sec61 inhibition.

nuaxia
Oct 142 min read


FDA approves Tukysa combination as first-line maintenance therapy for HER2-positive advanced breast cancer
The FDA has approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab as a first-line maintenance treatment for adults with HER2-positive advanced breast cancer.

nuaxia
Oct 82 min read


Medicus Pharma licenses Pfizer CD228V antibody-drug conjugate in deal worth more than $1bn
Medicus Pharma has secured exclusive worldwide rights to Pfizer's CD228-targeted antibody-drug conjugate PF-08046031 in an oncology licensing agreement potentially worth more than $1 billion.

nuaxia
Sep 142 min read


FDA approves Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for 2026–2027 season
The updated Comirnaty formulation targets the XFG variant and will begin shipping immediately for eligible older adults and people aged five to 64 at increased risk of severe COVID-19.

nuaxia
Aug 282 min read


European Commission authorises Pfizer-BioNTech XFG-adapted COVID-19 vaccine for the 2026–2027 vaccination season
The updated vaccine is authorised for individuals aged six months and older and aligns the EU COVID-19 vaccination programme with the currently circulating XFG variant.

nuaxia
Jul 312 min read


Innovent Biologics and Pfizer Form $10bn+ Oncology Alliance Across 12 Cancer Programs
The partnership expands a global co-development model spanning ADCs, multispecific antibodies, and early-stage oncology assets across US and China markets.

nuaxia
May 302 min read
bottom of page